Tag

Drug Pricing

All articles tagged with #drug pricing

politics10 days ago•1 min saved

Eric Cantor to Lead PhRMA as Pharma Faces Pricing and AI Scrutiny

Former House Majority Leader Eric Cantor has been appointed president and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA), effective November 9. He will succeed Steve Ubl, who is stepping down after 11 years. Cantor, a former Virginia Republican and current Moelis & Company executive, will lead the industry’s top lobbying group amid intense scrutiny over drug pricing, AI integration, and regulatory changes.

via Axios|

#drug-pricing #eric-cantor #pharmaceutical-industry

politics10 days ago•1 min saved

Eric Cantor to Lead PhRMA Amid Rising Pharma Scrutiny

Former House Majority Leader Eric Cantor has been named the next president and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA), effective November 9. He will succeed Steve Ubl, who is stepping down after 11 years. Cantor, a former Virginia Republican, joins the trade group at a critical time as the pharmaceutical industry faces intense scrutiny over drug pricing, tariffs, and vaccine safety from both the Trump administration and Congress. The appointment marks a shift toward a leader with significant business and political experience, though it has drawn mixed reactions regarding his partisan background.

via Politico|

#drug-pricing #eric-cantor #healthcare-policy

politics20 days ago•4 min saved

All 50 States Enlist in Trump’s MFN Drug Pricing for Medicaid, Promising Billions in Savings

All 50 states, Puerto Rico, and DC have joined Trump’s 'most favored nations' drug-pricing plan for Medicaid, pegging prices to eight high-income countries and reportedly saving Medicaid about $64 billion over 10 years and the government roughly $529 billion over a decade.

via New York Post|

#drug-pricing #healthcare-costs #medicaid

politics1 month ago•4 min saved

Trump expands voluntary drug-price deals with nine more manufacturers

President Trump announced a new round of voluntary drug-pricing agreements with nine manufacturers, bringing the total to 26 deals since the program began. The pledges include pricing drugs near the lowest international rates, applying most-favored-nation terms to Medicaid, and, in some cases, boosting domestic manufacturing and stockpiles. Details are not publicly released, and the overall impact on costs remains unclear.

via STAT|

#drug-pricing #healthcare-policy #medicaid

health-policy1 month ago•6 min saved

White House unveils nine new drug-price deals with pharma firms

The White House announced nine additional MFN-style drug-pricing deals with pharma firms (bringing total to 26) intended to lower prices for Medicaid and align U.S. prices with other wealthy nations; details are largely confidential, prompting calls from Democrats for transparency. The administration also highlights the Medicare GLP-1 Bridge Program, which has saved seniors money, and urges Congress to codify MFN pricing into permanent law.

via Politico|

#drug-pricing #glp-1-bridge-program #health-policy

politics1 month ago•2 min saved

Trump to unveil voluntary drug-price discounts tied to foreign prices

President Trump is set to announce that about a dozen drugmakers will voluntarily lower prices on outpatient drugs, expanding the administration’s push to tie U.S. prices to cheaper foreign rates under its 'most favored nation' policy. The effort follows deals with roughly 17 pharma companies over the past year and a May 2025 executive order reviving the policy. Participating manufacturers would offer discounts to state Medicaid programs (optional participation) and may be exempt from Medicare discount pilots, as part of a broader strategy to curb healthcare costs ahead of elections, while drugmakers expand direct-to-consumer channels such as the TrumpRx portal.

via CNBC|

#drug-pricing #medicaid #most-favored-nation

business1 month ago•19 min saved

Rasonque poised to reshape pancreatic cancer therapy with blockbuster potential

Revolution Medicines’ pancreatic cancer drug Rasonque will list at $39,800 for a 30-day supply, a price analysts say could help it become a blockbuster; Evercore ISI raised pancreatic cancer sales forecasts to about $2.4 billion next year and up to $15.1 billion by 2034, with potential expansion to other cancers. The FDA approved the drug for patients who’ve had one systemic therapy or aren’t candidates for multiagent therapy, and a Phase 3 front-line trial is underway, signaling strong launch momentum despite the steep price.

via BioPharma Dive|

#business #drug-pricing #fda-approval

health1 month ago•19 min saved

Pancreatic cancer drug arrives with a $39,800 monthly price, but costs depend on coverage and aid

FDA approves Revolution Medicines’ oral daraxonrasib (Rasonque) for metastatic pancreatic adenocarcinoma after phase 3 results showing a 60% reduction in death risk and median survival of 13.2 months versus 6.7 with chemotherapy. The wholesale list price is about $39,800 for a 30‑day supply (roughly $477,000/year), but patients’ out‑of‑pocket costs vary with insurance; Medicare Part D and discounts can reduce costs by about 20–30%, and aid programs (e.g., Path) may offer low or zero copays for eligible patients. Side effects include rash, diarrhea, mucositis, nausea, fatigue, and edema. The drug is not a cure but offers a life‑extending option for a historically hard‑to‑treat cancer; about 67,000 pancreatic cancer diagnoses are expected in 2026.

via Yahoo Finance|

#drug-pricing #fda-approval #financial-assistance

healthcare1 month ago•5 min saved

Rasonque Debuts in Pancreatic Cancer as Investors Eye a Historic Launch

Revolution Medicines wins FDA approval for Rasonque (daraxonrasib) in metastatic pancreatic cancer, triggering optimism of a historic oncology launch and potential multi‑billion sales, but raising questions about first‑line use, payer coverage, and how quickly patients move from expanded‑access to commercial treatment amid a $39,800 monthly price and a broad label whose criteria for multiagent therapy remain unclear.

via Fierce Pharma|

#drug-pricing #expanded-access-program #healthcare

health-policy1 month ago•11 min saved

Most states pass on Trump’s discounted GLP-1 deal, tightening Medicaid access

Trump’s plan to negotiate discounted GLP-1 weight‑loss drugs for Medicaid has stalled: only Indiana has signed on, while 29 states will not participate due to tight budgets. Twelve states still cover GLP-1s, but five of those recently ended coverage (California, Massachusetts, New Hampshire, Pennsylvania and South Carolina), with Rhode Island set to end in October. As other states weigh participation, many cite cost concerns and the risk to budget sustainability, meaning access to these drugs for low-income Americans on Medicaid is shrinking even as some argue these medications could reduce long-term health costs.

via Politico|

#drug-pricing #glp-1 #health-policy

business1 month ago•3 min saved

Hims & Hers CEO Defends FTC Case, Promises Cheaper GLP-1s and In-House AI

Hims & Hers CEO Andrew Dudum defends the company against an FTC lawsuit over data sharing and subscription practices, arguing the digital model increases access. He notes past price reductions from selling compounded GLP-1s, says Novo Nordisk dropped a patent suit and the firm now sells Novo’s branded drugs, and signals a move toward in-house AI to lower costs and transform healthcare.

via CNBC|

#ai-in-healthcare #business #drug-pricing

health2 months ago•6 min saved

Gilead's HIV PrEP Pricing Sparks Latin American Access Fight

Lenacapavir, a twice-yearly PrEP drug from Gilead that nearly prevents HIV infection, is priced at about $14,000 per dose in the US, while a reduced generic license aims for roughly $40 per dose in 120 low- and middle-income countries. Upper-middle-income Latin American countries like Brazil, Mexico, Argentina, and Peru don’t qualify, prompting protests and stalled negotiations over access. Officials and UNAIDS urge faster, broader access, as Gilead says it’s continuing regional talks and exploring other long-acting PrEP options to widen supply amid ongoing manufacturing constraints.

via Business Insider|

#access-to-medicines #drug-pricing #health

health3 months ago•50 min saved

Two Decades of GLP-1s: Obesity, Economy, and Culture in the Ozempic Era

A BuzzFeed News piece gathers Reddit discussions and user anecdotes to explore how GLP-1 medications (like Ozempic, Wegovy, and Mounjaro) could reshape society over 20 years. Predictions span obesity becoming a “disease of poverty,” shifts in beauty standards toward muscle or other traits, and the role of patent expirations and pricing in global access. The article also highlights potential economic and geopolitical effects, factory shifts in the food and insurance industries, and debates over long‑term health impacts and craving dynamics, all illustrating a future where widespread GLP-1 use could alter health, wealth, and culture.

via BuzzFeed|

#drug-pricing #glp-1-drugs #health

politics3 months ago•19 min saved

Trump drug-price rule targets 340B markups, forecasting $1.1B in Medicare savings

AP live updates report the Trump administration proposing a rule to bar hospitals from charging markups on discounted drugs for Medicare patients under the 340B program, potentially saving $1.1 billion next year; the feed also covers former CIA Director John Brennan's lawsuit to preserve records, Trump's maiden flight on a retrofitted Air Force One, his visit to the Theodore Roosevelt Presidential Library, and plans for Trump's Accounts that would give newborns $1,000.

via AP News|

#340b #brennan #drug-pricing

healthcare4 months ago•3 min saved

TrumpRx.gov Expansion Opens Transparent, Discounted Generics for Americans

President Trump announced an expansion of TrumpRx.gov to list more than 600 generic medications with transparent cash prices, enabling patients to compare the best cash prices at local pharmacies or delivery options against insurance co-pays, and integrating discounts from Amazon Pharmacy, Cost Plus Drugs, and GoodRx; the platform excludes controlled substances and meds not commonly offered direct-to-consumer, building on prior executive actions to lower US drug costs.

via The White House (.gov)|

#drug-pricing #generic-meds #healthcare